DOI:10.31557/APJCP.2023.24.7.2427
Comparison of Human Papillomavirus Genotype Detection in Paired Urine and Self-Collected Cervical Swabs
RESEARCH ARTICLE
Editorial Process: Submission:03/13/2023 Acceptance:07/02/2023
Comparison of Human Papillomavirus Genotype Detection in
Paired Urine and Self-Collected Cervical Swabs: A Pilot Study
Sangram Singh Patel1*, Nilanchali Singh2, Ashima Jamwal1, Chinmoy Sahu1,
Atul Garg1, Nisha Rao2, Nidhi Tejan1, Rashid Khan1
Abstract
Objectives: With the objective of establishing a simple, cost-effective, and effective screening tool for the screening
of Human Papilloma Virus infection, the study was undertaken. Materials and Methods: This pilot study was conducted
on 20 urine samples of women whose cervical swabs were tested positive while screening for Human papilloma virus
in asymptomatic women. Results: HPV genotypes were detected in 94% (16/17) patients in urine samples by realtime PCR while a 100% detection rate (15/15) was observed in the cervical swab samples. The results of the urine and
cervical swab samples, tested by the TRUPCR ®HPV high-risk genotyping kit, are shown in Table 2. HPV genotype
68 was found in 82.3% urinary samples and 100% of self-collected vaginal swab samples. Out of 16 positive urine
samples, 2 were positive for HPV genotype 16 and 5 were positive for HPV genotype 18, and in cervical swab testing
out of 15 positive samples, 3 were positive for HPV genotype 16, and 5 were positive for HPV genotype 18. Diagnostic
accuracy of urine was found to be 98.8% (95% CI 79.43% - 100.00%). Conclusion: This pilot study aims to assess the
accuracy of urine samples in the screening of HPV infection among asymptomatic women and establish the distribution
of prevalent HPV genotypes. This may further contribute to standardizing the urine and cervical swab testing methods
for cervical cancer screening strategies.
Keywords: Human Papilloma Virus- cervical swab- Urine samples- HPV genotypes
Asian Pac J Cancer Prev, 24 (7), 2427-2430
Introduction
Worldwide, cervical cancer is the fourth most common
cancer reported in women and is the second most common
cancer in women inhabiting low-income countries (Bhatla
and Singhal, 2020). The cancer is associated with the
Human papillomavirus (HPV) which is known to affect
the sexually active population at some point in their lives.
HPV is a small, non-enveloped deoxyribonucleic acid
(DNA) virus that has a special predilection for mucosal
cells (WHO Cervical cancer, 2022). The viral genome
contributes to over 100 HPV genotypes, of which 16 are
responsible for 70% of the cervical cancers.
The infection may be self-limiting or may result in
pre-cancerous and invasive cancer. In addition, access
to treatment for such cancerous lesions is limited in low
or middle-income countries which further attributes to a
high mortality rate of 13.3/100,000. This, however, can
be reduced by effective screening interventions and timely
diagnosis.
The PAP (Papanicolaou) test has been a preferred
screening tool (MacLaughlin et al., 2019) in the diagnosis
of cervical cancer but there are certain limitations like
incorrect information regarding the procedure, lack of
spousal or family support towards the test and the stigma
associated with cervical cancer contribute to the decreased
accession of the procedure among the rural population
(Taneja et al., 2021).
Screening strategies for cervical cytology or
Papanicolaou (PAP) testing require uncomfortable, and
pelvic examinations and the cytology results are often
susceptible to technical errors, low sensitivity, and false
negative results. Therefore, alternative, and supplementary
HPV DNA assays are often required in combination
with the traditional Pap smear test. Self-sampled vaginal
swabs are being used in screening programs at different
centres but their limitations like improper technique,
non-cooperation further add to the limited implementation
in the rural population (Adsul et al., 2019). Testing urine
samples may prove to be a successful alternative to
screening methods, especially in poor-resource countries.
The first void urine sample (Kim et al., 2022) contains
a higher percentage of exfoliated cells of the debris
compared to the mid-stream collection. Therefore, its
self-sampling is comfortable as well as easier compared
to the other sampling methods.
1
Department of Microbiology, SGPGIMS, Lucknow, India. 2Department of Obstetrics and Gynecology, AIIMS, New Delhi, India.
*For Correspondence: sangram87@gmail.com
Asian Pacific Journal of Cancer Prevention, Vol 24
2427
Sangram Singh Patel et al
Being inexpensive, non-invasive, and simple to collect,
urine samples make a promising tool for screening for
HPV infection. The majority of the Indian population
resides in rural areas with a lack of healthcare facilities
and poor accessibility to a well-equipped diagnostic setups. Hence, an efficient, effective and affordable tool for
screening of cervical cancer is required to significantly
reduce the burden of the disease by early diagnosis and
management.
This pilot study aims to assess the accuracy of
urine samples in the screening of HPV infection among
asymptomatic women and establish the distribution of
prevalent HPV genotypes. This may further contribute to
standardizing the urine and cervical swab testing methods
for cervical cancer screening strategies.
Materials and Methods
Study design 1
A cross-sectional study was conducted among
asymptomatic women in rural areas surrounding
Jagdishpur district, Uttar Pradesh. The asymptomatic
women in the age group of 18-65 were enrolled in the
study. The study was approved by the Institutional
Ethical Committee of Sanjay Gandhi Post-Graduate
Institute of Medical Sciences, Lucknow with Registration
Number: 2021-109-IMP-EXP-38 and Reference Number:
PGI/BE/303/2021 before commencing the protocol.
Collaboration with the local Primary Health care Centre
and subcentre was established to reach the participants.
Recruitment of subjects 1.1
The objectives of the study were explained to the
concerned staff at the CHC involved in the recruitment
of participants. Households were visited by the ASHA
(Accredited Social Health Activists) workers and subjects
willing to participate in the study were explained the
testing protocol and procedures in their local language.
Written informed consent from all the enrolled participants
was taken.
Community Health Centre (CHC) Jagdishpur was the
primary testing site for the self-collected Cervical swab
samples using the Truenat High risk HPV genotyping
kit18 (®Molbio Diagnostics, Goa, India) and 20 positive
cervical swab samples with their respective urine samples
were further tested for PCR genotyping at SGPGIMS to
ascertain the role of screening urine samples for HPV
detection. This pilot study was conducted on the 20
participants whose cervical swab samples had tested
positive by Trunat HPV kit at the Community health center.
The respective urine samples of these 20 participants were
collected after consent and both cervical swabs and urine
samples were sent to the department of microbiology,
SGPGIMS for PCR testing. The demographic details for
these 20 patients were recorded. The results of the PCR at
two centres were not compared as the genotype detection
varies in both the kits mentioned;
Specifications of the kits used at the testing sites:
2428
Asian Pacific Journal of Cancer Prevention, Vol 24
Table 1. Specifications of the Testing Kits Used
Name
Principle
Detection of genotypes
TRUPCR®HPV*
High-Risk
Genotyping Kit by
BlackBio Biotech
India Ltd
Real-time
amplification kit
14 HPV high/
intermediate risk types
16,18,31,33,35,39,45,5
1,52,56,58 59,66,68
Trunat® HRHPV* by molbio
diagnostics
Real-time
amplification kit
4 HPV high risk types
16,18,31 and 45
*Abbreviations: HPV, Human Papilloma Virus; HR-HPV, High Risk
Human Papilloma Virus
Testing protocol 1.1.1
An early stream random urine sample and a selfcollected cervical swab were collected and transported
to the microbiology laboratory at 4-80C in a transport
medium.
All (20) urine and vaginal samples were tested by
TRUPCR ®HPV High-Risk Genotyping Kit as per the
testing protocol (Table 1).
Data analysis 2.0
Out of the 20 samples (urine and cervical swabs),
3 urine samples and 5 cervical swab samples were
insufficient in quantity and could not be processed
further. Therefore, 17 urine and 15 cervical swabs were
tested using the TRUPCR ®HPV High-Risk Genotyping
Kit19 (Table 3). Categorical variables were described
using percentages and a Chi-square test was applied. All
Statistical analyses were performed using SPSS statistical
software (IBM SPSS version 26, Armonk, N.Y.).
Results
HPV genotypes were detected in 94% (16/17) patients
in urine samples by real-time PCR while a 100% detection
rate (15/15) was observed in the cervical swab samples.
The results of the urine and cervical swab samples, tested
by TRUPCR ®HPV high-risk genotyping kit, are shown
in Table 2. HPV genotype 68 was found in 82.3% urinary
samples and 100% of self-collected vaginal swab samples.
Out of 16 positive urine samples, 2 were positive for HPV
genotype 16 and 5 were positive for HPV genotype 18
and in cervical swab testing out of 15 positive samples, 3
were positive for HPV genotype 16 and 5 were positive
for HPV genotype 18.
Discussion
Cervical screening is crucial, as cervical cancer can
be prevented in more than 90% of cases. Cytological
screening for the early detection of cervical cancer
precursors has been carried out successfully in developed
countries. HPV-DNA testing has been shown to be more
sensitive than cytological analysis and may thus be an
alternative to cervical scrapes (Lorenzi et al., 2018).
Vaginal and urine self-sampling methods have been shown
to be more acceptable for patients and result in increased
participation when available in the screening programs
field (Ducancelle et al., 2014). Using urine as a sample
for HPV DNA testing is still debated. In this setting, the
DOI:10.31557/APJCP.2023.24.7.2427
Comparison of Human Papillomavirus Genotype Detection in Paired Urine and Self-Collected Cervical Swabs
Figure 1. Comparison of Urine and Cervical Swab Samples in the Detection of High Risk HPV Genotypes.
objectives of the present paper were to compare HPV
DNA detection in urine and self-collected vaginal swab
samples.
Urinary HPV testing is performed on the basis that
urine can be used for the detection of HPV as the epithelial
wall of the uterine cervix and/or vagina normally sheds
exfoliated cells into the urine and if there is HPV or any
other microbial infections, the shredded cells should
contain viral genomes virions including genomes of
other infectious organisms. Therefore first void urine
sampling has been utilized for the detection of HPV by
several authors (Bober et al., 2021; Leeman et al., 2017;
Torres-Rojas et al., 2021; Vorsters, Van Damme, et al.,
2014). A study Nilyanimit et al., (2017) suggests that
urine represents a viable substitute for cervical swabs
in detecting HPV. Urine samples are a good option for
self-sampling screening since they are non-invasive and
simple to collect.
In the present study, first void urine and cervical
swab samples were studied by TRUPCR® HPV HighRisk Genotyping Kit. The cervical samples were already
tested positive by the Trunat PCR kit at the testing
site in Jagdishpur district. The Trunat PCR HR-HPV
Table 2. Distribution of HPV Genotypes Detected in
Urine and Cervical Swab Samples
HPV Genotype
detected
genotyping kit is not standardized for the testing of urine
samples, hence the urine samples were transported to the
microbiology laboratory at SGPGIMS for further testing
by real-time PCR. Although the prevalence of HPV
infection was slightly higher in the vaginal samples, but
it is not significantly different from what has been found
in urine samples. The most important finding in our
study was that urine samples show a diagnostic accuracy
(Table 3) of 98.8% which is significantly higher than the
other diagnostic modalities available. While comparing
to a meta-analysis done by Peter et al., (2021) and Bober
et al., (2021); a heterogeneity was detected between
the pooled sensitivities and specificities, i.e., pooled
sensitivity for high-risk HPV detection in urine was 78%
(70% to 84%) and specificity was 89% (81% to 94%). For
any HPV detection in the urine of 87% (74% to 94%) and
91% (83% to 96%), we pooled sensitivity and specificity,
respectively. HPV 16 and 18 had a pooled sensitivity of
77% (76% to 77%) and a specificity of 98% (98% to 98%).
The results from our study suggest that using urine
sampling to detect genital HPV infection can be a very
useful and convenient tool for the non-invasive screening
of symptom-free normal healthy women who may have
high-risk HPVs. The technique is simple and costeffective. However, urine samples contain insufficient
cervical cells and may vary depending on collection,
storage, DNA extraction, and study population (Vorsters
et al., 2012; Vorsters et al., 2014) Therefore, it is necessary
to develop appropriate collection, storage, and DNA
extraction methods to efficiently use urine samples as
HPV test samples. The results of testing urine samples
Urine samples
(n=17)
Total tested= 17
Positive= 16
Cervical swabs
(n=15)
Total tested= 15
Positive= 15
68
14 (82.3%)
15 (100%)
18
05 (29.41%)
05 (33.3%)
59
04 (23.5%)
02 (13.3%)
51
03 (17.6%)
04 (26.6%)
Statistical accuracy
Value (%)
95% CI
66
02 (11.7%)
05 (33.3%)
Sensitivity
94.12%
71.31% - 99.85%
16
02 (11.7%)
03 (20%)
Specificity
100.00%
2.50% - 100.00%
31,33
02 (11.7%)
02 (13.3%)
Positive Predictive Value (*)
100.00%
-
39,52,58
02 (11.7%)
01 (6.6%)
Negative Predictive Value (*)
98.55%
91.04% - 99.78%
35
01 (5.8%)
01 (6.6%)
Accuracy (*)
98.82%
79.43% - 100.00%
*HPV, Human Papilloma Virus
Table 3. Diagnostic Accuracy of Urine Samples in the
Estimation of HPV Infection.
(*) based on the prevalence of the disease taken as 20%.
Asian Pacific Journal of Cancer Prevention, Vol 24
2429
Sangram Singh Patel et al
for the determination of HPV genotypes look promising
and require thorough research before implementing it as
a screening tool.
Strengths and Limitations: This is a pilot study
involving only 20 participants. Therefore, these results
cannot be directly extrapolated to a screening population
due to small sample size. The study highlights the
implementation of urine as a useful screening tool which
can be further tested on a large population to establish its
accuracy in estimation of HPV infection in Indian women.
In conclusion, This pilot study shows that testing of
first catch urinary samples is comparable to self-collected
vaginal swabs in detecting HPV infection and hence,
can make a promising tool in the screening of HPV in
comparison to the poorly acceptable cervical sampling
procedures. This might show some more hope in
bringing out urinary samples as an alternative screening
methodology.
Author Contribution Statement
Dr. Sangram, Dr. Nilanchali; Data curation:
Dr. Sangram, Dr. Nilanchali; Formal analysis:Dr.
Chinmoy, Dr. Atul, ; Investigation: Dr. Nisha, Dr. Nidhi;
Methodology: Dr. Sangram, Dr. Nilanchali, Dr. Ashima;
Writing - original draft: Dr. Sangram, Dr. Nilanchali, Dr.
Ashima; Writing -review and editing: Dr. Chinmoy, Dr.
Atul, Dr. Nidhi.
Acknowledgements
The authors would like to thank the staff at CHC
Jagdishpur for their constant support.
Ethical Approval
The study was approved by the Institutional Ethical
Committee of Sanjay Gandhi Post-Graduate Institute of
Medical Sciences, Lucknow with Registration Number:
2021-109-IMP-EXP-38 and Reference Number: PGI/
BE/303/2021 before commencing the protocol.
Ducancelle A, Legrand MC, Pivert A, et al (2014). Interest of
human papillomavirus DNA quantification and genotyping
in paired cervical and urine samples to detect cervical
lesions. Arch Gynecol Obstet, 290, 299–308.
HPV Information Centre (n.d.) (2023). ICO/IARC Information
Centre on HPV and Cancer (HPV Information Centre).
Retrieved January 3, from https://hpvcentre.net.
Kim DH, Jin H, Lee KE (2022). Analysis of HR-HPV Infection
Concordance Rates in Cervical and Urine Specimens;
Proposal of Additional Cervical Screening Process for
Women Who Refuse Invasive Cervical Sampling. J Pers
Med, 12, 1949.
Leeman A, Del Pino M, Molijn A, et al (2017). HPV testing in
first-void urine provides sensitivity for CIN2+ detection
comparable with a smear taken by a clinician or a brushbased self-sample: Cross-sectional data from a triage
population. BJOG, 124, 1356–63.
Lorenzi AT, Fregnani JHT, Dockter J, et al (2018). High-Risk
Human Papillomavirus Detection in Urine Samples From
a Referral Population With Cervical Biopsy-Proven HighGrade Lesions. J Low Genit Tract Dis, 22, 17–20.
MacLaughlin KL, Jacobson RM, Radecki Breitkopf C, et al
(2019). Trends Over Time in Pap and Pap-HPV Cotesting for
Cervical Cancer Screening. J Womens Health, 28, 244–49.
Nilyanimit P, Chansaenroj J, Karalak A, et al (2017).
Comparison of human papillomavirus (HPV) detection in
urine and cervical swab samples using the HPV GenoArray
Diagnostic assay. Peer J, 5, e3910.
Taneja N, Chawla B, Awasthi AA, et al (2021). Knowledge,
Attitude, and Practice on Cervical Cancer and Screening
Among Women in India: A Review. Cancer Control, 28,
107327482110107.
Torres-Rojas FI, Mendoza-Catalán MA, Alarcón-Romero LDC,
et al (2021). HPV molecular detection from urine versus
cervical samples: An alternative for HPV screening in
indigenous populations. Peer J, 9, e11564.
Vorsters A, Micalessi I, Bilcke J, et al (2012). Detection of
human papillomavirus DNA in urine. A review of the
literature. Eur J Clin Microbiol Infect Dis, 31, 627–40.
Vorsters A, Van Damme P, Clifford G (2014). Urine testing
for HPV: Rationale for using first void. BMJ, 349, g6252–
Vorsters A, Van Den Bergh J, Micalessi I, et al (2014).
Optimization of HPV DNA detection in urine by improving
collection, storage, and extraction. Eur J Clin Microbiol
Infect Dis, 33, 2005–14.
Conflict of interest
None declared.
References
Adsul P, Srinivas V, Gowda S, et al (2019). A community‐based,
cross‐sectional study of hr HPV DNA self‐sampling‐based
cervical cancer screening in rural Karnataka, India. Int J
Gynaecol Obstet, 146, 170–6.
Bhatla N, Singhal S (2020). Primary HPV screening for cervical
cancer. Best Practice & Research. Clin Obstet Gynecol, 65,
98–108.
Bober P, Firment P, Sabo J (2021). Diagnostic Test Accuracy
of First-Void Urine Human Papillomaviruses for Presence
Cervical HPV in Women: Systematic Review and MetaAnalysis. Int J Environ Res Public Health, 18, 13314.
Cervical cancer (n.d.) (2022). WHO. Human Papillomavirus
(HPV) and Cervical Cancer; World Health Organization:
Geneva, Switzerland. Retrieved January 3, 2023, from
https://www.who.int/news-room/fact-sheets/detail/cervicalcancer.
2430
Asian Pacific Journal of Cancer Prevention, Vol 24
This work is licensed under a Creative Commons AttributionNon Commercial 4.0 International License.